LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

14.24 -1.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.8

Максимум

14.37

Ключови измерители
By Trading Economics
Приходи	-23M -14M
Продажби	-22M 72M
EPS	-0.09
Марж на печалбата	-18.944
Служители	624
EBITDA	-23M -6.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+43.66% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-505M 2.3B
Предишно отваряне	15.69
Предишно затваряне	14.24

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.03.2026 г., 20:38 ч. UTC

Печалби

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

10.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10.03.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10.03.2026 г., 23:06 ч. UTC

Печалби

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10.03.2026 г., 22:51 ч. UTC

Значими събития в новините

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10.03.2026 г., 21:39 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10.03.2026 г., 21:21 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10.03.2026 г., 21:15 ч. UTC

Печалби

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10.03.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10.03.2026 г., 21:14 ч. UTC

Печалби

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10.03.2026 г., 21:13 ч. UTC

Печалби

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q Rev $597.3M >FNV

10.03.2026 г., 21:12 ч. UTC

Печалби

Franco-Nevada 4Q EPS $1.90

10.03.2026 г., 20:57 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

10.03.2026 г., 20:44 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

10.03.2026 г., 20:34 ч. UTC

Пазарно говорене

Печалби

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10.03.2026 г., 20:23 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10.03.2026 г., 20:16 ч. UTC

Печалби

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10.03.2026 г., 20:14 ч. UTC

Печалби

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10.03.2026 г., 20:13 ч. UTC

Печалби

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10.03.2026 г., 20:12 ч. UTC

Печалби

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

43.66% нагоре

12-месечна прогноза

Среден 20.86 USD 43.66%

Висок 22 USD

Нисък 20 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.